Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc.
Tempus AI
Actym Therapeutics, Inc.
University of California, San Diego
Aminex Therapeutics, Inc.
Inhibrx Biosciences, Inc
Novartis
Pfizer
Hoffmann-La Roche
Seagen Inc.
Repertoire Immune Medicines
Dynavax Technologies Corporation
Tocagen Inc.
Dartmouth-Hitchcock Medical Center
CureOne
sigma-tau i.f.r. S.p.A.
Celldex Therapeutics
Yale University
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center